DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17333335Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/21893226 | https://www.ncbi.nlm.nih.gov/pubmed/20014777 | https://www.ncbi.nlm.nih.gov/pubmed/21862726 | https://www.ncbi.nlm.nih.gov/pubmed/21030469
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17333335
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/21893226 | https://www.ncbi.nlm.nih.gov/pubmed/20014777 | https://www.ncbi.nlm.nih.gov/pubmed/21862726 | https://www.ncbi.nlm.nih.gov/pubmed/21030469
Farnesol, (2E,6E)- is an isoprenoid found in many aromatic plants and is also produced in humans, where it acts on numerous nuclear receptors and has received considerable attention due to its apparent anticancer properties. Farnesol is present in many essential oils such as citronella, neroli, cyclamen, lemon grass, tuberose, rose, musk, balsam, and tolu. It is used in perfumery to emphasize the odors of sweet floral perfumes. Its method of action for enhancing perfume scent is as a co-solvent that regulates the volatility of the odorants. It is especially used in lilac perfumes. Farnesol is a natural pesticide for mites and is a pheromone for several other insects. In a 1994 report released by five top cigarette companies, farnesol was listed as one of 599 additives to cigarettes. Farnesol has been suggested to function as a chemopreventative and anti-tumor agent. Farnesol is subject to restrictions on its use in perfumery as some people may become sensitized to it, however, the evidence that farnesol can cause an allergic reaction in humans is disputed.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2051 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20014777 |
81.4 µM [IC50] | ||
Target ID: CHEMBL1287617 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21030469 |
47.0 µM [IC50] | ||
Target ID: CHEMBL2047 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21893226 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Antifungal properties of essential oils and their main components upon Cryptococcus neoformans. | 1994 Dec |
|
Antimycobacterial activity of (E)-phytol and derivatives: a preliminary structure-activity study. | 1998 Feb |
|
Xol INXS: role of the liver X and the farnesol X receptors. | 2001 Apr |
|
Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. | 2002 Jan 11 |
|
Evaluation of morphogenic regulatory activity of farnesoic acid and its derivatives against Candida albicans dimorphism. | 2002 Mar 25 |
|
Lysine beta311 of protein geranylgeranyltransferase type I partially replaces magnesium. | 2004 Jul 16 |
|
Omega-hydroxylation of farnesol by mammalian cytochromes p450. | 2004 Jun 1 |
|
Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation. | 2008 Jan |
|
Roles of rat and human aldo-keto reductases in metabolism of farnesol and geranylgeraniol. | 2011 May 30 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21862726
mice were maintained for 5 wk on adiet containing 0.25%, 0.5% farnesol
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17333335
The ER-positive MCF-7 breast cancer cell line and MDAMB-231 breast carcinoma cells (ATCC HTB-26) lacking ER expression were used for activity evaluation. Cells were cultured at 37C in a humidified 95% air and 5% CO2 atmosphere. One day after seeding, the culture medium was replaced by fresh SFM containing farnesol (10-200mkM, MP Biomedicals, Aurora, OH), 17b-estradiol (Sigma, St Louis, MO), 4-hydroxytamoxifen (Sigma, St Louis, MO), the raloxifen analog LY 117,018 (a gift from Eli Lilly & Co., Indianapolis, IN), fulvestrant (ICI 182,780, Tocris, Bristol, UK), ibandronate (a gift from Hoffmann-LaRoche, Basel, Switzerland), mevastatin (Sigma, St Louis, MO), or vehicle. Cells were treated for 1–3 days, with drugs alone or in combinations. The FXR activator farnesol, a mevalonate pathway intermediate, exerts a mitogenic effect on MCF-7 cells.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EC SCIENTIFIC COMMITTEE ON CONSUMER SAFETY OPINION |
SCCS/1459/11
Created by
admin on Sat Dec 16 20:01:21 GMT 2023 , Edited by admin on Sat Dec 16 20:01:21 GMT 2023
|
||
|
EPA PESTICIDE CODE |
128910
Created by
admin on Sat Dec 16 20:01:21 GMT 2023 , Edited by admin on Sat Dec 16 20:01:21 GMT 2023
|
||
|
JECFA EVALUATION |
FARNESOL
Created by
admin on Sat Dec 16 20:01:21 GMT 2023 , Edited by admin on Sat Dec 16 20:01:21 GMT 2023
|
||
|
CFR |
21 CFR 172.515
Created by
admin on Sat Dec 16 20:01:21 GMT 2023 , Edited by admin on Sat Dec 16 20:01:21 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
42680
Created by
admin on Sat Dec 16 20:01:21 GMT 2023 , Edited by admin on Sat Dec 16 20:01:21 GMT 2023
|
PRIMARY | |||
|
DTXSID3032389
Created by
admin on Sat Dec 16 20:01:21 GMT 2023 , Edited by admin on Sat Dec 16 20:01:21 GMT 2023
|
PRIMARY | |||
|
EB41QIU6JL
Created by
admin on Sat Dec 16 20:01:21 GMT 2023 , Edited by admin on Sat Dec 16 20:01:21 GMT 2023
|
PRIMARY | |||
|
DB02509
Created by
admin on Sat Dec 16 20:01:21 GMT 2023 , Edited by admin on Sat Dec 16 20:01:21 GMT 2023
|
PRIMARY | |||
|
SUB169860
Created by
admin on Sat Dec 16 20:01:21 GMT 2023 , Edited by admin on Sat Dec 16 20:01:21 GMT 2023
|
PRIMARY | |||
|
m5245
Created by
admin on Sat Dec 16 20:01:21 GMT 2023 , Edited by admin on Sat Dec 16 20:01:21 GMT 2023
|
PRIMARY | Merck Index | ||
|
1362903
Created by
admin on Sat Dec 16 20:01:21 GMT 2023 , Edited by admin on Sat Dec 16 20:01:21 GMT 2023
|
PRIMARY | RxNorm | ||
|
EB41QIU6JL
Created by
admin on Sat Dec 16 20:01:21 GMT 2023 , Edited by admin on Sat Dec 16 20:01:21 GMT 2023
|
PRIMARY | |||
|
445
Created by
admin on Sat Dec 16 20:01:21 GMT 2023 , Edited by admin on Sat Dec 16 20:01:21 GMT 2023
|
PRIMARY | |||
|
28600
Created by
admin on Sat Dec 16 20:01:21 GMT 2023 , Edited by admin on Sat Dec 16 20:01:21 GMT 2023
|
PRIMARY | |||
|
225-004-1
Created by
admin on Sat Dec 16 20:01:21 GMT 2023 , Edited by admin on Sat Dec 16 20:01:21 GMT 2023
|
PRIMARY | |||
|
4602-84-0
Created by
admin on Sat Dec 16 20:01:21 GMT 2023 , Edited by admin on Sat Dec 16 20:01:21 GMT 2023
|
PRIMARY | |||
|
1239
Created by
admin on Sat Dec 16 20:01:21 GMT 2023 , Edited by admin on Sat Dec 16 20:01:21 GMT 2023
|
PRIMARY | |||
|
60597
Created by
admin on Sat Dec 16 20:01:21 GMT 2023 , Edited by admin on Sat Dec 16 20:01:21 GMT 2023
|
PRIMARY | |||
|
D005204
Created by
admin on Sat Dec 16 20:01:21 GMT 2023 , Edited by admin on Sat Dec 16 20:01:21 GMT 2023
|
PRIMARY | |||
|
FARNESOL
Created by
admin on Sat Dec 16 20:01:21 GMT 2023 , Edited by admin on Sat Dec 16 20:01:21 GMT 2023
|
PRIMARY |
Any of these components may be present:
SUBSTANCE RECORD